Evidence map›Paper›PMID 31291057›Full record

Observational studyJournal of the International AIDS Society2018

Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.

Aminata Mboup, Luc Béhanzin, Fernand A Guédou, Nassirou Geraldo, Ella Goma-Matsétsé, Katia Giguère, Marlène Aza-Gnandji, Léon Kessou, Mamadou Diallo, René K Kêkê and 13 more

Abstract readObservational Study
In one paragraph

Observational study in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Aminata MboupDépartement de médecine sociale et préventive, Université Laval, Québec, QC, Canada.
Luc BéhanzinAxe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada.
Fernand A GuédouAxe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada.
Nassirou GeraldoDispensaire IST, Centre de santé communal de Cotonou 1, Cotonou, Bénin.
Ella Goma-MatsétséDispensaire IST, Centre de santé communal de Cotonou 1, Cotonou, Bénin.
Katia GiguèreDépartement de médecine sociale et préventive, Université Laval, Québec, QC, Canada.ORCID 0000-0001-5043-426X
Marlène Aza-GnandjiDispensaire IST, Centre de santé communal de Cotonou 1, Cotonou, Bénin.
Léon KessouService de Consultance et Expertise Nouvelle en Afrique (SCEN AFRIK), Cotonou, Bénin.
Mamadou DialloDépartement de médecine sociale et préventive, Université Laval, Québec, QC, Canada.
René K KêkêProgramme Santé de Lutte contre le Sida (PSLS), Cotonou, Bénin.
Moussa BachabiProgramme Santé de Lutte contre le Sida (PSLS), Cotonou, Bénin.
Kania DramaneLaboratoire de virologie du Centre Muraz, Bobo-Dioulasso, Burkina Faso.
Lily GeidelbergDepartment of infectious disease, Imperial College London, London, UK.
Fiona CianciUniversity of Bristol, Bristol, UK.
Christian LafranceAxe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada.
Dissou AffolabiFaculté des sciences de la santé, Université d'Abomey-Calavi, Cotonou, Bénin.
Souleymane DiabatéDépartement de médecine sociale et préventive, Université Laval, Québec, QC, Canada.
Marie-Pierre GagnonAxe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada.
Djimon M ZannouFaculté des sciences de la santé, Université d'Abomey-Calavi, Cotonou, Bénin.
Flore GangboProgramme Santé de Lutte contre le Sida (PSLS), Cotonou, Bénin.
Marie-Claude BoilyAxe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec - Université Laval, Québec, QC, Canada.
Peter VickermanUniversity of Bristol, Bristol, UK.ORCID 0000-0002-8291-5890
Michel AlaryDépartement de médecine sociale et préventive, Université Laval, Québec, QC, Canada.ORCID 0000-0002-0246-4429

Funding

CIHR FDN-143218CIHR ROH-115205Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

introductionIn sub-Saharan Africa, HIV prevalence remains high, especially among key populations. In such situations, combination prevention including clinical, behavioural, structural and biological components, as well as adequate treatment are important. We conducted a demonstration project at the Dispensaire IST, a clinic dedicated to female sex workers (FSWs) in Cotonou, on early antiretroviral therapy (E-ART, or immediate "test-and-treat") and pre-exposure prophylaxis (PrEP). We present key indicators such as uptake, retention and adherence.

methodsIn this prospective observational study, we recruited FSWs from October 4th 2014 to December 31st 2015 and followed them until December 31st 2016. FSWs were provided with daily tenofovir disoproxil fumarate/emtricitabine (Truvada

resultsAmong FSWs in the catchment area, HIV testing coverage within the study framework was 95.5% (422/442). At baseline, HIV prevalence was 26.3% (111/422). Among eligible FSWs, 95.5% (105/110) were recruited for E-ART and 88.3% (256/290) for PrEP. Overall retention at the end of the study was 59.0% (62/105) for E-ART and 47.3% (121/256) for PrEP. Mean (±SD) duration of follow-up was 13.4 (±7.9) months for E-ART and 11.8 (±7.9) months for PrEP. Self-reported adherence was over 90% among most E-ART participants. For PrEP, adherence was lower and the proportion with 100% adherence decreased over time from 78.4% to 56.7% (p-trend < 0.0001). During the 250.1 person-years of follow-up among PrEP initiators, two seroconversions occurred (incidence 0.8/100 person-years (95% confidence interval: 0.3 to 1.9/100 person-years)). The two seroconverters had stopped using PrEP for at least six months before being found HIV-infected. In both groups, there was no evidence of reduced condom use.

conclusionsThis study provides data on key indicators for the integration of E-ART and PrEP into the HIV prevention combination package already offered to FSWs in Benin. PrEP may be more useful as an individual intervention for adherent FSWs rather than a specific public health intervention. E-ART was a more successful intervention in terms of retention and adherence and is now offered to all key populations in Benin. STUDY REGISTRATION: ClinicalTrials.gov NCT02237.

Indexed as

Pre-Exposure ProphylaxisSex WorkersAdultAnti-HIV AgentsBeninEmtricitabineFemaleHIV InfectionsHumansProspective StudiesSafe SexSexual BehaviorTenofovirAnti-HIV AgentsEmtricitabineTenofoviradherenceearly antiretroviral therapyfemale sex workersHIV preventionpre-exposure prophylaxisretention

Identifiers

PMID31291057
PMCPMC6287093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.